You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
SharePoint
Sign In
Follow
Alternative for Time-Based Media
Patient Surge Strategies: NYC Health + Hospitals 2018: Alternative Description for Time-Based Media
Patient Surge Strategies 2018 Lehigh Valley Health System: Alternative Description for Time-Based Media
HPP Turns 15: Alternative Description for Time-Based Media
DRIVe - Sepsis: Alternative Description for Time-Based Media
DRIVe - Personal Devices: Alternative Description for Time-Based Media
DRIVe - Transforming Health Security: Alternative Description for Time-Based Media
Introducing DRIVe
Scott Needle, MD - Introduction to NACCD: Alternative Description for Time-Based Media
Dr. Prabhavathi Fernandes, Ph.D. | Introduction to the National Biodefense Science Board: Alternative for Time-Based Media
Tranquil Terminus: Alternative Description for Time-Based Media
CARB-X: Alternative Description for Time-Based Media
Kevin Yeskey: Regional Disaster Health Response System - Alternative Description for Time-Based Media
Byron Mason: Disaster Recovery Coordination - Alternative Description for Time-Based Media
Byron Mason: Benefits of an Early Start to Health and Social Services Recovery Operations - Alternative Description for Time-Based Media
HHS medical teams provide care after Hurricane Michael - Alternative Description for Time-Based Media
The Emergency Prescription Assistance Program - Alternative Description for Time-Based Media
Mapping the Capacity of Healthcare in Puerto Rico - Alternative Description for Time-Based Media
Biography
David Christian Hassell, PhD,
Jonathan Greene
Request an ASPR Speaker
Kacey Wulff
Dawn O'Connell
Nikki Bratcher-Bowman
Federal Public Health Actions
MCM Procurements and Grants
Currently selected
Hurricane Sandy - Public Health Situation Updates
Site Contents
Skip over global navigation links
Office of the Assistant Secretary for Preparedness and Response
Preparedness
Emergency
About ASPR
Public Health Emergency - Leading a Nation Prepared
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
PHE Home
>
PHE Newsroom
>
MCM Procurements and Grants
MCM Procurements and Grants
Main Content
August 11, 2020: Trump Administration collaborates with Moderna to produce 100 million doses of COVID-19 investigational vaccine
February 11, 2020: HHS, Janssen Join Forces On Coronavirus Vaccine
October 30, 2019: HHS to advance development of Cytovale rapid sepsis diagnostic
September 25, 2018: HHS sponsors new formulation of world’s first approved smallpox drug
July 16, 2018: HHS, DoD, Spero co-sponsor novel oral antibiotic development to treat deadly infections
October 3, 2017: HHS sponsors development of two tests for radiation exposure
October 3, 2017: HHS, Regeneron partner on portfolio of treatments for pandemic influenza, emerging infectious diseases
August 29, 2017: FDA approves new antibacterial drug
July 25, 2017: CARB-X Announces Funding for Global Scientists Racing to Discover New Antibiotics to Treat Superbugs
March 27, 2017: Antimicrobial Resistance Diagnostic Challenge selects 10 semifinalists in first phase of competition
September 8, 2016: Federal prize competition seeks innovative ideas to combat antimicrobial resistance
September 8, 2016: HHS awards $350,000 to American Academy of Pediatrics to help children affected by the Zika Virus
October 1, 2015: BARDA sponsors development of new skin substitute to treat large burns
October 1, 2015: BARDA sponsors development of new skin substitute to treat large burns
September 30, 2015: HHS sponsors innovative approaches to improve influenza vaccines
September 30, 2015: HHS enhances preparedness with new products to treat severe burns
September 30, 2015: HHS pursues fast, easy test for anthrax and multi-drug resistant anthrax infections
September 29, 2015: HHS advances development of novel drug to treat influenza
September 28, 2015: HHS sponsors development of drug for hospitalized influenza patients
September 25, 2015: HHS pursues development of panels of blood-based biomarkers for several biothreat pathogens
September 23, 2015: HHS explores new disaster use of approved ‘clot busting’ drug
September 22, 2015: Mass decontamination research provides new scientific evidence for responders, hospitals to decontaminate chemical terrorism, accident survivors
September 21, 2015: HHS advances development of new monoclonal antibody drug for Ebola
September 16, 2015: HHS enters into strategic alliance to accelerate new antibiotic development
September 14, 2015: Experimental Ebola vaccine regimen takes new steps under HHS program
August 17, 2015: Development of new anthrax vaccine underway with HHS support
July 20, 2015: HHS partnership advances experimental Ebola drug
June 12, 2015: HHS pursues fast, easy test to detect Ebola virus infections
March 31, 2015: HHS contracts to develop new Ebola drug
March 23, 2015: HHS seeks to develop improved anthrax vaccine
October 16, 2014: HHS advances development of Ebola vaccine
October 1, 2014: HHS pursues detection tests for influenza
September 29, 2014: HHS funds drug to treat severe infections and prevent cytokine storm
September 24, 2014: New device could reduce time needed to test for bacteria, such as anthrax
December 23, 2014: HHS supports efforts to speed Ebola vaccine delivery
September 17, 2014: HHS spurs innovation to develop next-generation portable ventilator
September 15, 2014: New diagnostic test to detect the presence of an influenza virus and identify its genetic profile
September 2, 2014: HHS contracts with Mapp Biopharmaceutical to develop Ebola drug
March 11, 2014: HHS establishes new network to perform clinical studies
February 5, 2014: HHS funds drug for bioterrorism, antimicrobial-resistant infections
September 26, 2013: BARDA boosts global ability to respond to pandemics
September 23, 2013: New blood test would provide fast results for medical care after anthrax attack
September 20, 2013: HHS funds development of freeze-dried platelets for disaster response
September 19, 2013: BARDA funds development of device to aid burn patients in disasters
September 19, 2013: HHS replenishes nation’s supply of anthrax antitoxin
September 18, 2013: HHS explores new emergency response use for approved steroid
September 17, 2013: BARDA funds study of therapy for thermal burns
September 16, 2013: BARDA evaluates burn dressing for radiation, sulfur mustard burns
August 23, 2013: BARDA Contract Supports Evaluation of Therapy for Severe Thermal Burns
August 22, 2013: BARDA Supports Proof-Of-Concept Studies for Small Molecule Development
July 30, 2013: BARDA contract supports the development of a more effective skin graft to help burn patients after a rad/nuke event
June 25, 2013: BARDA supports new broad-spectrum antibiotic against glanders, melioidosis
May 24, 2013: BARDA supports new broad-spectrum antibiotic to treat anthrax, tulermia
May 22, 2013: HHS forms strategic alliance to develop new antibiotics
April 2, 2013: HHS awards contract to create test to identify resistant influenza viruses
December 13, 2012: BARDA, Johns Hopkins Partner to Explore Impact of Rapid, Near-Patient Flu Tests
January 20, 2012: HHS aids development of next generation broad spectrum antibiotic
September 29, 2011: BARDA funds development of oral drug to treat internal contamination from radioactive elements
September 28, 2011: Contract awarded to develop drug to protect against radiation-induced gastrointestinal injury
September 28, 2011: Studies to continue in development of new way to treat blood damage from radiation
September 28, 2011: Cushing’s disease drug studied for possible use in treating gastrointestinal injuries from radiation exposure
September 16, 2011: Licensed anthrax vaccine undergoes temperature studies
September 15, 2011: BARDA funds advanced development of drug to treat bone marrow injury associated with acute radiation syndrome
September 15, 2011: Novel Anthrax Vaccine Being Developed with BARDA Support
September 6, 2011: BARDA partners with GlaxoSmithKline to develop new class of antibiotic against bioterrorism threats and Gram-negative infections
August 31, 2011: Anti-inflammatory drug studied for use 24 hours or longer after exposure to radiation
August 30, 2011: BARDA funds advanced development of drug to treat injuries from exposure to cyanide
August 30, 2011: BARDA supports development of antitoxin administered as a traditional shot
August 30, 2011: BARDA funds development of drugs to treat injuries from chemical bioterrorism
Right Box1 Content
Right Box2 Content
About BARDA
BARDA Strategic Plan
Procurement and Grant Awards
Program Divisions
Project BioShield Annual Reports
Leadership Biographies
This page last reviewed: March 23, 2018
